Top

Published in:

Open Access 01-04-2018 | Original Article

Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung

Authors: Luka Brcic, Stefanie Stanzer, Dagmar Krenbek, Ulrike Gruber-Moesenbacher, Gudrun Absenger, Franz Quehenberger, Arschang Valipour, Joerg Lindenmann, Herbert Stoeger, Mohamed Al Effah, Melanie Fediuk, Marija Balic, Helmut H. Popper

Published in: Virchows Archiv | Issue 4/2018

Abstract

Squamous cell and adenocarcinomas of the lung develop different mechanisms during carcinogenesis to evade attacks of the immune system. Besides the well-known check-point control programmed death 1 and its ligand, many more mechanisms, acting either tumoricidal or in favor of tumor progression, exist. Analysis of the immune cell profiles in resected tissues and bronchoalveolar lavage samples and correlation between them and with overall survival data was performed. In all tumor samples in this study, cells of the immune system expressed a tumor-cooperating phenotype. High numbers of regulatory T cells, or alternatively expression of Vista on lymphocytes was present. Tumoricidal dendritic cells were absent in tumor tissue, and barely present in bronchoalveolar lavage, whereas tumor-friendly monocytoid and plasmocytoid dendritic cells were seen in both. Alveolar macrophages were predominantly differentiated into tumor-cooperating M2 types, whereas tumoricidal M1 macrophages were absent or rare. The expression of PDL1 on tumor cells did not correlate with any other immune cells. Expression of PD1 on lymphocytes was frequently encountered. None of analyzed immune cells showed correlation with overall survival. Immune cells in bronchoalveolar lavage and tissue did not correlate. For the first time, a tissue-based analysis of different immune cells in squamous cell and adenocarcinomas of the lung is provided, trying to explain their potential role in tumor development and progression. Discordant numbers of cells with bronchoalveolar lavage are most probably due to the fact that bronchoalveolar lavage reflects the situation in the whole lung, where chronic obstructive lung disease and other conditions are present.

Available only for authorised users

Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, Mountzios G, de Mello RA (2016) The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy 8:479–488. https://doi.org/10.2217/imt-2015-0002 CrossRefPubMed

Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM (2017) Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. https://doi.org/10.1093/neuonc/now287

Barth SD, Schulze JJ, Kuhn T, Raschke E, Husing A, Johnson T, Kaaks R, Olek S (2015) Treg-mediated immune tolerance and the risk of solid cancers: findings from EPIC-Heidelberg. J Natl Cancer Inst 107:djv224. https://doi.org/10.1093/jnci/djv224 CrossRefPubMed

Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M (2016) Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 5:e1057388. https://doi.org/10.1080/2162402x.2015.1057388 CrossRefPubMed

Blidner AG, Salatino M, Mascanfroni ID, Diament MJ, Bal de Kier Joffe E, Jasnis MA, Klein SM, Rabinovich GA (2015) Differential response of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory agent indomethacin in tumor-associated and tumor-free microenvironments. J Immunol 194:3452–3462. https://doi.org/10.4049/jimmunol.1401144 CrossRefPubMed

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465. https://doi.org/10.1056/NEJMoa1200694 CrossRefPubMedPubMedCentral

Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, Stenvold H, Camps C, Busund LT (2011) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 6:824–833. https://doi.org/10.1097/JTO.0b013e3182037b76 CrossRefPubMed

Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321–330. https://doi.org/10.1038/nature21349 CrossRefPubMed

Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD Sr, Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA (2015) Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 33:74–82. https://doi.org/10.1200/jco.2014.57.3329 CrossRefPubMed

10.

Dumitriu IE, Dunbar DR, Howie SE, Sethi T, Gregory CD (2009) Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 182:2795–2807. https://doi.org/10.4049/jimmunol.0712671 CrossRefPubMed

11.

Enk AH (2005) Dendritic cells in tolerance induction. Immunol Lett 99:8–11. https://doi.org/10.1016/j.imlet.2005.01.011 CrossRefPubMed

12.

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837–1846. https://doi.org/10.1016/s0140-6736(16)00587-0 CrossRefPubMed

13.

Fletcher M, Ramirez ME, Sierra RA, Raber P, Thevenot P, Al-Khami AA, Sanchez-Pino D, Hernandez C, Wyczechowska DD, Ochoa AC, Rodriguez PC (2015) L-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res 75:275–283. https://doi.org/10.1158/0008-5472.can-14-1491 CrossRefPubMed

14.

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567. https://doi.org/10.1038/nature14011 CrossRefPubMedPubMedCentral

15.

Hoeppner LH, Wang Y, Sharma A, Javeed N, Van Keulen VP, Wang E, Yang P, Roden AC, Peikert T, Molina JR, Mukhopadhyay D (2015) Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. Mol Oncol 9:270–281. https://doi.org/10.1016/j.molonc.2014.08.008 CrossRefPubMed

16.

Karachaliou N, Cao MG, Teixido C, Viteri S, Morales-Espinosa D, Santarpia M, Rosell R (2015) Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. Cancer Biol Med 12:79–86. https://doi.org/10.7497/j.issn.2095-3941.2015.0029 PubMedPubMedCentral

17.

Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, Gulley JL, Schlom J, Farsaci B (2014) Pan-Bcl-2 inhibitor, GX15-070 (Obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol 192:2622–2633. https://doi.org/10.4049/jimmunol.1301369 CrossRefPubMedPubMedCentral

18.

Liu Q, Zhang C, Sun A, Zheng Y, Wang L, Cao X (2009) Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol 182:6207–6216. https://doi.org/10.4049/jimmunol.0803926 CrossRefPubMed

19.

Liu Y, Chen K, Wang C, Gong W, Yoshimura T, Liu M, Wang JM (2013) Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophages. Cancer Res 73:550–560. https://doi.org/10.1158/0008-5472.can-12-2290 CrossRefPubMed

20.

Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21:24–33. https://doi.org/10.1016/j.molmed.2014.10.009 CrossRefPubMed

21.

Peggs KS, Quezada SA (2012) PD-1 blockade: promoting endogenous anti-tumor immunity. Expert Rev Anticancer Ther 12:1279–1282. https://doi.org/10.1586/era.12.109 CrossRefPubMed

22.

Riedl K, Baratelli F, Batra RK, Yang SC, Luo J, Escuadro B, Figlin R, Strieter R, Sharma S, Dubinett S (2003) Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer 2:35. https://doi.org/10.1186/1476-4598-2-35 CrossRefPubMedPubMedCentral

23.

Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, Ratto GB, Grossi F, Truini M, Pistillo MP (2012) Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother 61:1463–1472. https://doi.org/10.1007/s00262-012-1211-y CrossRefPubMed

24.

Sawant A, Schafer CC, Jin TH, Zmijewski J, Tse HM, Roth J, Sun Z, Siegal GP, Thannickal VJ, Grant SC, Ponnazhagan S, Deshane JS (2013) Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res 73:6609–6620. https://doi.org/10.1158/0008-5472.can-13-0987 CrossRefPubMed

25.

Sawant A, Schafer CC, Ponnazhagan S, Deshane JS (2014) The dual targeting of immunosuppressive cells and oxidants promotes effector and memory T-cell functions against lung cancer. Oncoimmunology 3:e27401. https://doi.org/10.4161/onci.27401 CrossRefPubMedPubMedCentral

26.

Scrimini S, Pons J, Agusti A, Clemente A, Sallan MC, Bauca JM, Soriano JB, Cosio BG, Lopez M, Crespi C, Sauleda J (2015) Expansion of myeloid-derived suppressor cells in chronic obstructive pulmonary disease and lung cancer: potential link between inflammation and cancer. Cancer Immunol Immunother 64:1261–1270. https://doi.org/10.1007/s00262-015-1737-x CrossRefPubMed

27.

Sharma SK, Chintala NK, Vadrevu SK, Patel J, Karbowniczek M, Markiewski MM (2015) Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs. J Immunol 194:5529–5538. https://doi.org/10.4049/jimmunol.1403215 CrossRefPubMed

28.

Simpson KD, Templeton DJ, Cross JV (2012) Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol 189:5533–5540. https://doi.org/10.4049/jimmunol.1201161 CrossRefPubMedPubMedCentral

29.

Suzuki K, Sun R, Origuchi M, Kanehira M, Takahata T, Itoh J, Umezawa A, Kijima H, Fukuda S, Saijo Y (2011) Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med 17:579–587. https://doi.org/10.2119/molmed.2010.00157 CrossRefPubMedPubMedCentral

30.

Sznol M, Chen L (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19:1021–1034. https://doi.org/10.1158/1078-0432.ccr-12-2063 CrossRefPubMedPubMedCentral

31.

Teglasi V, Reiniger L, Fabian K, Pipek O, Csala I, Bago AG, Varallyai P, Vizkeleti L, Rojko L, Timar J, Dome B, Szallasi Z, Swanton C, Moldvay J (2017) Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. Neuro Oncol. https://doi.org/10.1093/neuonc/now309

32.

Wang W, Hodkinson P, McLaren F, MacKinnon A, Wallace W, Howie S, Sethi T (2012) Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate. Int J Cancer 131:E928–E937. https://doi.org/10.1002/ijc.27613 CrossRefPubMed

33.

Wang Y, Sparwasser T, Figlin R, Kim HL (2014) Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Res 74:2217–2228. https://doi.org/10.1158/0008-5472.can-13-2928 CrossRefPubMed

34.

Wang YC, He F, Feng F, Liu XW, Dong GY, Qin HY, Hu XB, Zheng MH, Liang L, Feng L, Liang YM, Han H (2010) Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 70:4840–4849. https://doi.org/10.1158/0008-5472.can-10-0269 CrossRefPubMed

35.

Yang CY, Lin MW, Chang YL, Wu CT, Yang PC (2014) Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 50:1361–1369. https://doi.org/10.1016/j.ejca.2014.01.018 CrossRefPubMed

36.

Zong J, Keskinov AA, Shurin GV, Shurin MR (2016) Tumor-derived factors modulating dendritic cell function. Cancer Immunol Immunother 65:821–833. https://doi.org/10.1007/s00262-016-1820-y CrossRefPubMed

Title: Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung
Authors: Luka Brcic
Stefanie Stanzer
Dagmar Krenbek
Ulrike Gruber-Moesenbacher
Gudrun Absenger
Franz Quehenberger
Arschang Valipour
Joerg Lindenmann
Herbert Stoeger
Mohamed Al Effah
Melanie Fediuk
Marija Balic
Helmut H. Popper
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 4/2018
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2326-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP)

The first report of a 5-year period cancer registry in Greece (2009–2013): a pathology-based cancer registry

Histopathological findings of pregnancy-induced hypertension: histopathology of early-onset type reflects two-stage disorder theory

CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8+/Foxp3+ T cells

Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study

Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?